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Abstract
Background: We have identified syndecan-2 as a protein potentially involved in perineural invasion of pancreatic
adenocarcinoma (PDAC) cells.
Methods: Syndecan-2 (SDC-2) expression was analyzed in human normal pancreas, chronic pancreatitis and PDAC
tissues. Functional in vitro assays were carried out to determine its role in invasion, migration and signaling.
Results: SDC-2 was expressed in the majority of the tested pancreatic cancer cell lines while it was upregulated in
nerve-invasive PDAC cell clones. There were 2 distinct expression patterns of SDC-2 in PDAC tissue samples: SDC-2
positivity in the cancer cell cytoplasm and a peritumoral expression. Though SDC-2 silencing (using specific siRNA
oligonucleotides) did not affect anchorage-dependent growth, it significantly reduced cell motility and invasiveness
in the pancreatic cancer cell lines T3M4 and Su8686. On the transcriptional level, migration-and invasion-associated
genes were down-regulated following SDC-2 RNAi. Furthermore, SDC-2 silencing reduced K-ras activity,
phosphorylation of Src and - further downstream - phosphorylation of ERK2 while levels of the putative SDC-2
signal transducer p120GAP remained unaltered.
Conclusion: SDC-2 is a novel (perineural) invasion-associated gene in PDAC which cooperates with K-ras to induce
a more invasive phenotype.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is still one of
the most lethal human malignancies due to late clinical
detection and its innate aggressiveness, stemming from
its potential for early local invasion and metastasis [1-3].
Among a variety of genomic alterations in precursor
lesions of PDAC (pancreatic intraepithelial neoplasia,
PanIN), mutations in the gene encoding the small
GTPase K-ras are most frequent and are currently
believed to be one of the initiating steps in pancreatic
carcinogenesis. Approximately 90% of the later stage
pancreatic cancers are found to be K-ras mutated and
seem to get “addicted” to K-ras overactivity (induced by
K-ras mutation), which might in turn have implications
for therapeutically targeting the K-ras pathway [4,5].
Apart from the mitogenic signal transduced by K-ras
overactivity, it also increases the transdifferentiation
from an epithelial cellular structure to a more mesench-
ymal phenotype. This particularly includes an increased
migratory and invasive potential which is a “prerequi-
site” for invasion and distant metastasis. Regarding the
local spread, perineural invasion (PNI) is a characteristic
property of PDAC cells allowing the tumor to infiltrate
adjacent organs and organ-structures. PNI is also
believed to be one of the major causes of the severe
pain syndrome accompanying advanced PDAC stages
[6]. Within this process of invasion, tumor cells are
interacting with and are producing (or are stimulating
stromal cells to produce) proteins of the extracellular
matrix (ECM), as well as cytokines, chemokines, cell-
adhesion proteins and growth factors [7]. These active
interactions then allow the tumor cells to coopt the
tumor stroma [8]. In addition, cell surface receptors and
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pating in tumor cell-stromal cell (i.e. nerves) communi-
cation. Among these, syndecans have recently attracted
considerable attention. Syndecans are transmembrane
heparan sulphate proteoglycans to which one or more
glycosaminoglycan chains are covalently attached [9].
The heparan sulphate chains of syndecans have an
extraordinary structural diversity, owing to differences
in the position of the sulphate groups along the polysac-
charide chain and epimerization of glucuronic acid resi-
dues to iduronic acid [10]. Four members of the
syndecan family have been indentified to date, and all
seem to be tissue-specific and to have distinct functions.
We have previously characterized the expression of syn-
decan-1 in pancreatic, esophageal, gastric, colon, and
liver human cancer tissues, and demonstrated that syn-
decan-1 is up-regulated in pancreatic cancer but not in
the other gastrointestinal malignancies, revealing that its
expression might play an important role in the patho-
biology of this disease [11]. Recently, using a novel ex
vivo perineural invasion model, we have identified 25
perineural-invasion-relatedg e n e s[ 1 2 ] .N o w ,u s i n gt h e
same ex vivo model, we identified syndecan-2 (SDC-2)
expression to be up-regulated in pancreatic cancer cell
clones which have an increased perineural invasive capa-
city. SDC-2 is a 21 kDa transmembrane protein with a
short cytoplasmic domain that contains two constant
regions (C1 and C2) separated by a variable region (V)
that is unique for each syndecan family member. On
immunoblots, SDC-2 is found as a stable dimer or oli-
gomer at 40-50 KDa [13-16]. It is highly expressed in
cells of mesodermal origin, and some reports have
described it as a tumor suppressor [17], whereas others
demonstrated that it functions as a promoter of tumori-
genesis [18,19]. Recently, SDC-2 was associated with the
migratory potential of melanoma cells and appears to
act as a general protumorigenic receptor in those cells
[20].
In our study, we report for the first time that SDC-2
promotes in vitro migration and invasion and that it
cooperates with K-ras to induce a more malignant pan-
creatic cancer phenotype in vitro.
Materials and methods
Cell culture
Pancreatic cancer cells were routinely grown in DMEM
or RPMI medium (Invitrogen, Karlsruhe, Germany),
supplemented with 10% FBS (PAN Biotech, Germany),
100 U/ml penicillin and 100 μg/ml streptomycin, as
described previously [21].
Tissue sampling
Pancreatic tissue specimens were obtained from patients
who underwent resection (median age 67 years, 32-85
years) for pancreatic cancer. Normal pancreas tissues
were obtained through an organ donor program from
previously healthy individuals. The Ethics Committee of
the Universities of Heidelberg and Munich, Germany,
approved the tissue collection. Written informed con-
sent was obtained from all patients.
Real-time quantitative polymerase chain reaction (QRT-
PCR)
For SDC-2 mRNA expression analysis, 7 pancreatic can-
cer cell lines and 82 samples of human pancreas tissues
(20 donors; 20 chronic pancreatitis; 42 PDAC), were
used (clinical characteristics of PDAC patients: Table 1).
Equipment and reagents were from Roche (Basel, Swit-
zerland), except for the mRNA extraction kit (RNeasy
Mini kit, Qiagen, Hilden, Germany) and the specific oli-
gonucleotides (Metabion, Munich, Germany). A dena-
turing agarose gel was used to assess integrity of the
extracted RNA. cDNA was prepared using the first-
strand cDNA synthesis kit for RT-PCR according to the
manufacturer’s instructions (Fermentas International
Inc., Canada). The primer sequence used for SDC-2
detection was 5’-ACATCTCCCCTTTGCTAACGGC-3’
(forward) and 5’-TAACTCCATCTCCTTCCCCAGG-3’
(reverse), Tm 58°C; human Cortactin (CTTN) 5’-
TCACTTTGTAGGAAACTCATCTCCTT-3’ (forward)
and 5’-GTGTGCTACAGGAATTCAGATACAAT-3’
(reverse), Tm 58°C; human WASF-1/2 5-TCCT
GATGTTTTAAAAGAAGAAACACT-3’ (forward)
and 5-AAAAGTTTTTAACTCCTATAGGCAAGC-3’
(reverse), Tm 58°C; human Cdc42 5-AGGCTCTCTA
GTTTAATAAAAATCATGG-3’ (forward) and 5- GTT
TGTTTAATACATCTGAAAAGAATGC-3’ (reverse),
Tm 58°C, and carried out using the LightCycler™480
with the SYBR Green 1 Master (Roche). The relative
Table 1 Characterization of PDAC tissues used in QRT-
PCR analysis
Total Patients 42
Median Age 66
Sex
Males 18
Females 24
T1 00
T2 03
T3 39
N0 09
N1 33
M0 39
M1 03
G1 02
G2 23
G3 17
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GAPDH using the LightCycler™480 software release
1.5, version 1.05.0.39 (Roche).
Immunohistochemistry
Immunohistochemistry was performed as previously
described [12,22] using 92 formalin-fixed, paraffin-
embedded samples (clinical characteristics: Table 2).
Rabbit anti-human pancytokeratin antibody (Abcam)
and rabbit anti-human syndecan-2 antibody (Invitrogen)
were used at a concentration of 1:100, diluted in anti-
body diluent (DAKO, Glostrup, Denmark). To confirm
the specificity of the primary antibody, tissue sections
were incubated with negative control rabbit IgG or the
syndecan-2 immunizing peptide (R&D Systems, MN,
1:10 dilution). Semi-quantitative evaluation was per-
formed by 2 independent researches as follows: SDC-2
tumor cell expression versus no tumor cell expression
and/or SDC-2 peritumoral expression versus no peritu-
moral expression.
Immunoblot analysis
Immunoblot analysis was performed as previously
described [23], using the following antibodies: rabbit
anti-syndecan-2 (Invitrogen), rabbit anti-phospho-ERK,
mouse anti-total-Src (7 G9), mouse anti-phospho-Src
(Tyr416; all from Cell Signaling, Danvers, MA), rabbit
anti-ERK-2 (Abcam, Cambridge, UK), mouse anti-
p120GAP and rabbit anti-GAPDH (both Santa Cruz
Biotech., Santa Cruz, CA). For the analysis of serum-free
cell supernatants (40 μl), these were subjected to SDS-
PAGE under reducing conditions, without pre-heating
(data not shown). To identify the SDC-2 core protein
(21 KDa), we enzymatically treated Su8686 cleared cell
lysates with 6 M urea in sodium acetate (ph 4.5), and
boiled them at 95°C for 10 min. Subsequently, the sam-
ples were centrifuged at 12.000 rpm (+4°C), for 10 min-
utes and the supernatants used for further analyses.
Additionally, the samples were treated twice with hepar-
inase III, 1 mU/ml or 2 mU/ml, at 42°C for 30 min.
Densitometric analyses were performed using the
“Image J” software http://rsbweb.nih.gov/ij/.
RNA interference
For transient mRNA silencing, approximately 15 × 10
4
cancer cells per well in 6-well plates were transfected
with 20 μM RNAi/well syndecan-2 Silencer Selected™
siRNA (Ambion/Applied Biosystems, Carlsbad, CA),
sequence s12637, 5’-GCUUCAGGAGUGUAUUC-
CUAtt-3’ (sense), 5’-UAGGAUACACUCCUGAAGCtt-3’
(antisense) and sequence s12635, 5’-UGACCUUGGA-
GAACGCAAAtt-3’ (sense), 5’-UUUGCGUUCUCCAAG-
GUCAta-3’ (antisense) using Hiperfect™ transfection
reagent (Qiagen, Hilden, Germany). Scrambled siRNA
(Ambion) was used as a control.
Matrigel invasion assay
Invasion assays were performed as previously described
[24,25]. 15 × 10
3 T3M4 and Su8686 cells which had
been transfected with SDC-2 or control siRNA
(scrambled) prior to seeding into the Boyden chamber
were seeded into the top chamber and were incubated
for 24 h. Cells adhering to the lower surface were fixed
with 75% methanol and 25% acetone and were stained
with Mayer’s Hematoxylin. The invading cells were
counted under a light microscopy (Zeiss Axioskop 40).
The assays were performed in triplicate and were
repeated three times.
Proliferation assays
Anchorage-dependent cell growth was determined using
the 3-(4,5-methylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) colorimetric growth assay. Briefly, 2,000
cells/well were plated in 96-well plates and were cul-
tured for up to 3 days. Each day, cell growth was deter-
mined by adding MTT solution (50 μg/well) for 4 h.
Cellular MTT was solubilised with acidic isopropanol
and optical density was measured at 570 nm. The dou-
bling time was calculated for the exponential growth
phase. All experiments were performed 3 times in
triplicates.
Immunofluorescence analysis
Cells were seeded at 1 × 10
5/well, in 8-wells glass chamber
slides (NUNC, New York, NY) and were grown overnight.
The cells were then fixed with 4% Paraformaldehyde,
washed with 1 × PBS, and permeabilized with 0.1% Triton
X-100/PBS, followed by blocking with 20 mM glycine/
PBS. Rabbit anti-human syndecan-2 was added at a
Table 2 Characterization of PDAC tissues used in IHC
analysis
Total Patients 92
Median Age 67
Sex
Males 57
Females 35
T1 01
T2 04
T3 87
N0 13
N1 79
M0 76
M1 16
G1 03
G2 42
G3 47
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lowed by incubation with anti-rabbit FITC-conjugated
antibody (dilution of 1:1000) and the DAPI dye (dilution
of 1:20000, both from G&E Health Care, Backinghamshire,
UK). Images were taken on a Zeiss Axioskop 40 or Apoto-
me™(both Carl Zeiss, Jena, Germany).
Migration assay
T3M4 and Su8686 cells were seeded into μ-dish-35 mm
low culture inserts according to the manufacturer’si n s t r u c -
tions (ibidi Integrated BioDiagnostics, Munich, Germany).
After 12 hours, the silicon brackets were removed and cell
migration was observed in 12-hour intervals, until 48 hours
post RNAi. Images were taken using a Canon A610 camera
(Canon Inc., Tokio, Japan) on an Axiovert 40 CFL inverted
microscope (Carl Zeiss, Jena, Germany). Analyses were car-
ried out using the Adobe Photoshop™ CS4 software
(Adobe Systems Inc., San Jose, CA) and GraphPad Prism
™ 5 (GraphPad Software, Inc., La Jolla, CA).
Immunoprecipitation assays
For SDC-2 immunoprecipitation (IP), a protein G-agar-
ose kit was used (IP50, Sigma-Aldrich, St. Louis, MO),
according to the manufacturer’s instructions. Pancreatic
cancer cells (Su8686 and BxPC3) were lysed on ice in 1
× IP buffer and were centrifuged for 10 minutes at
12.000 rpm. Nuclei and debris were removed and the
samples were transferred into IP columns for incubation
with rabbit anti-human SDC-2 antibody. After 2 hours
+4°C, the eludate was incubated with protein G-agarose
at +4°C, overnight. Precipitates were washed 5 times
with ice-cold 1× IP buffer, eluted with 1× Laemmli sam-
ple buffer, and boiled for 10 minutes. Bound proteins
were subjected to SDS-polyacrylamide gel electrophor-
esis and were electrotransferred onto nitrocellulose
membranes. The membranes were then subjected to
m o u s ep 1 2 0 G A Pa n t i b o d y( S a n t aC r u zB i o t e c h . )o rr a t
anti-human SDC-2 (R&D Systems, Minneapolis, MN).
Ras activity assay
Fresh cell lysates were treated according to the manu-
facturer’s instructions (Millipore/Upstate, Temecula,
CA). Briefly, total cell lysates, cleared of nuclei and deb-
ris by 5 min centrifugation, were incubated for 90 min,
at 4°C, with beads coated with a fusion protein (GST-
Raf1-RBD) consisting of GST fused to the Ras binding
domain of Raf-1. Beads were washed three times with
ice cold 1× MLB buffer. The bound protein was eluted
by 10 min boiling with 2× Laemmli sample buffer and
was analyzed by immunoblotting for Ras activity.
Statistical analysis
Differences in survival between the tumor cell expres-
sion/no-expression and expression around tumor cells/
no expression groups were analyzed using the Kaplan-
Meier method. Results are expressed as mean ± stan-
dard error of the mean (SEM), unless otherwise stated.
Significance was set at p < 0.05. The statistical analyses
were performed using the GraphPad Prism™ 5 software
(GraphPad Software).
Results
Using an ex vivo model of perineural invasion in pan-
creatic cancer [12], we have found upregulation of syn-
decan-2 in nerve-invasive pancreatic cancer cell clones.
In this study, we used descriptive methods on human
pancreatic cancer tissues and genetic manipulation in
vitro to further assess the role of syndecan-2 in pancrea-
tic cancer with an emphasis on elucidating its role in
invasion and motility as surrogates of the locally
advanced and metastatic disease.
SDC-2 is upregulated in nerve-invasive pancreatic cancer
cells
We compared expression of SDC-2 in less nerve-invasive
pancreatic cancer cell clones (passage 0, i.e. before ex
vivo nerve invasion) to clones which had been subjected
to ex vivo nerve invasion (passage 3) using quantitative
RT-PCR (QRT-PCR) and immunoblot analysis. These
assays revealed an upregulation of SDC-2 mRNA and
protein (cell lysates, c/l) levels in passage 3 nerve-invasive
cancer cell clones (Figure 1, 2); however, this was not
constantly reflected in the secretory compartment where
- due to unknown reasons such as differential secretion
or cleavage - upregulation of SDC-2 was only observed in
Colo-357 passage 3 cells (data not shown). RT-PCR of
mRNAs from a larger set of pancreatic cancer cell lines
substantiated these results by demonstrating that in seven
cell lines, SDC-2 transcripts were found (Figure 1, B1,
normal colon = positive control). The cell lines, in which
SDC-2 was transcribed, were also SDC-2-positive on the
protein level (seven tested cell lines, normal colon as a
positive control, Figure 1, B2). Interestingly, and in line
with previous studies, the SDC-2 core protein was found
in its dimerized form at 42 kDa (Figure 1, D). Because
di- and oligomerization are essential for the function of
syndecans [26,27] and are dependent on the presence of
glycosaminoglycan side chains [9], we decided to enzyma-
tically deglycate the cell lysates. Using this assay, we iden-
tified the unglycanated form of SDC-2 (at 21 kDa) in
immunoblot analysis (Figure 1, D. Su8686 cells). To gain
insight into the potential function of SDC-2 in vivo, we
quantitatively analyzed its mRNA expression in bulk pan-
creatic tissues from healthy donors (normal pancreas, NP,
n = 20), from chronic pancreatitis patients (CP, n = 20)
and pancreatic ductal adenocarcinoma (PDAC, Table 1. n
= 42). Unexpectedly, SDC-2 mRNA was downregulated
in PDAC (p < 0.001, Figure 1, C).
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Page 4 of 10SDC-2 expression in pancreatic tissue
In a next step, we performed immunohistochemistry on
tissue samples of normal pancreas, pancreatic intrae-
pithelial neoplasia (PanIN), pancreatic cancer (PDAC),
and pancreatic cancer with perineural invasion (PNI),
( F i g u r e2 A ,T a b l e2 ) .W h i l ei nt h en o r m a lp a n c r e a s ,
there was a moderate to strong staining for SDC-2 in
acinar cells and no or weak staining around ducts, there
was strong immunoreactivity for SDC-2 around pan-
creatic intraepithelial neoplasia lesions (Figure 2, A2, 5;
both in PanINs from malignant and non-transformed
tissues, arrows). In PDAC, different patterns of cellular/
stromal distribution of SDC-2 were found: around some
cancer structures, SDC-2 deposition was seen at differ-
ent intensities (Figure 2, A6, 7) whereas some cancers
showed only cytoplasmic cancer cell positivity for SDC-
2 (Figure 2, A6; arrow); in other PDACs, nuclear SDC-2
staining was present (Figure 2, A7). Cancer cells which
invaded pancreatic nerve structures were generally SDC-
2-positive. Using a semi-quantitative evaluation, we
compared the SDC-2 expression patterns in tissues from
92 pancreatic cancer patients. While in 48 tissues, peri-
tumoral SDC-2 expression was found (out of these, a
minority also showed cytoplasmatic cancer cell staining),
in 24 tissues there was SDC-2 positivity in the cyto-
plasm of the cancer cells. 20 tissue samples were nega-
tive for SDC-2. Kaplan-Meier survival analysis of the
groups with versus without SDC-2 cancer cell expres-
sion and peritumoral versus no peritumoral SDC-2
expression demonstrated that none of the observed
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Figure 1 (A-D) A-1, QRT-PCR, SDC-2 mRNA levels in nerve invasive cancer cells; A-2, SDC-2 protein levels in cell lysates (c/l); GAPDH as
a loading control; “Fold expression” has been calculated using densitometry of the immunoblots which were normalized to GAPDH.
B-1, QRT-PCR, SDC-2 mRNA levels in PDAC cell lines (normal colon as a positive control). B-2, SDC-2 protein levels in PDAC cell lysates (normal
colon as positive control). C, QRT-PCR, SDC-2 mRNA levels in human normal pancreas (donor), CP and PDAC tissues. D, enzymatically treated
SU8686 cell lysates; NT = not treated; (1) = 6 M urea in sodium acetate ph 4,5 treated; (2) = 6 M urea in sodium acetate ph 4,5 plus 1 mU/ml
Heparinase III; (3) = 1 mU/ml Heparinase III treatment; and (3) = 2 mM/ml Heparinase III treatment.
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Page 5 of 10expression patterns were associated with survival (Figure
2B; upper panel, median survival 14 vs. 16 months;
lower panel, median survival 16 vs. 15 months). Accord-
ing to these results, we hypothesized that these expres-
sion patterns (and secretion patterns) might be reflected
in vitro; however, immunofluorescence analyses only
confirmed a granular cytoplasmic localization of SDC-2
(Figure 2C; comparable to SDC-2 localization in pros-
tate cancer cells [28]). Thus, in a next step, we analyzed
the function of SDC-2 in pancreatic cancer cells in vitro.
SDC-2 knockdown decreases pancreatic cancer cell
migration and invasion and reduces K-ras/MAPK pathway
signaling
Because SDC-2 has been associated with tumorigenicity
in sarcoma, fibrosarcoma, melanoma and colon cancer
cells [20,29-31], we set out to determine whether modu-
lation of SDC-2 expression in pancreatic cancer cells
would affect their motility and their invasive capacity in
vitro. To this end, we used the T3M4 (previously used
for the PNI experiments, [12]) and the Su8686 cell lines
due to their SDC-2 expression levels and K-ras muta-
tional status [32]. Using a specific siRNA, SDC-2 levels
were significantly reduced in both cell lines for up to 72
h (Figure 3, 1, 2; for reduction of SDC-2 protein levels
following RNAi see Figure 4C). Since syndecans have
been suggested to modulate proliferation signaling via
receptor tyrosine kinase interference [27,33-37], we then
tested the effects of SDC-2 RNAi on cell growth using
standardized MTT assays; however, no significant differ-
ences were observed comparing control RNAi-trans-
fected to SDC-2 RNAi-transfected cells (Figure 3, 1, 2).
In contrast, cell migration was significantly reduced 24
ha n d3 6ha f t e rR N A i( F i g u r e3 ,1 ,2 ;p<0 . 0 0 0 1a t2 4
h and 36 h for both cell lines, respectively), as was the
number of invaded cells in the matrigel invasion assay
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Figure 2 (A-C) A, IHC staining of different pancreatic tissues using an anti-SDC-2 antibody (A1-7) and an anti-pan-cytokeratin antibody
(A8); A: acinar cells, N: nerve(s). B, Kaplan-Maier survival curves of patients with tumor cell-expressing/non-expressing tissues or with/without
expression around tumor cells; C, immunofluorescence staining of Su8686, T3M4 and Panc-1 pancreatic cancer cells using an anti-SDC-2
antibody.
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lines, respectively). To corroborate these findings on a
transcriptional level, we assessed expression levels of
three migration- and cytoskeletal organization-associated
genes: cortactin (CTTN) has been shown to regulate
interactions between components of adherens junctions,
to be involved in cytoskeleton organization, cell adhe-
sion and to be a substrate for Src [38]; Wiskott-Aldrich
syndrome protein family member 1 (WASF1) is involved
in transduction of signals from receptors on the cell sur-
face to the actin cytoskeleton. Recent studies have
demonstrated that these protein family, directly or indir-
ectly, associate with the small GTPase CDC42 (cell divi-
sion cycle 42), known to regulate formation of actin
filaments, and the cytoskeletal organizing complex,
Arp2/3 [14,39]. Compatible with our functional observa-
tion that SDC-2 regulates cell migration and invasive-
ness, expression levels of these genes were strikingly
r e d u c e d2 4ha f t e rS D C 2R N A ii nT 3 M 4c e l l s( a n d
remained suppressed for up to 72 h; Figure 3D). In
Su8686 cells, SDC-2 RNAi induced an approximately
40% reduction in CTTN and WASF1 levels and a 25%
reduction in CDC42 expression after 24 h; after 72 h
expression levels returned to baseline (Figure 3D, right
panel).
Recent reports have shown that syndecan-2 interferes
with K-ras/MAPK signaling via association with p120-
G A Pt of u n c t i o na sa na c t i v es w i t c hs i g n a lf o rS r ci n
cells transformed with oncogenic ras [40-42]. Since the
Su8686 cell line, which we used in our experiments, is
K-ras-mutated and has thus constitutive overactivity of
K-ras signaling (higher than the other tested cell lines;
Figure 4A, upper panel), we determined whether SDC-2
silencing would affect K-ras and MAPK activity. In a
first step, we immunoprecipitated SDC-2 in BxPC3 (low
K-ras activity, wildytpe K-ras [43,44]), and Su8686 cells
(high K-ras activity, K-ras-mutated [32]) and analyzed
whether p120-GAP was bound to the precipitated SDC-
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Figure 3 A-D, functional assays following silencing of SDC-2 in T3M4 and Su8686 cells. A1-2, QRT-PCR following SDC-2 RNAi; B1-2,
proliferation assays; C1-2, migration assays; C3-4, matrigel invasion assays; D, QRT-PCR analysis of the expression levels of migration-and
cytoskeleton-associated gens 24, 48 and 72 hours after SDC2 silencing.
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no p120-GAP was bound to SDC-2 (Figure 4B, right)
whereas in Su8686 cells, a strong p120-GAP signal was
detected (Figure 4B, right). We thus concluded that
p120-GAP binding to SDC-2 was associated with the K-
ras activity of the respective cell lines. To determine
whether there was a direct relation between SDC-2
expression levels and K-ras/MAPK, p120 and Src signal-
ing, we silenced SDC-2 in Su8686, T3M4 and 8988 T
pancreatic cancer cells and analyzed ras activity, levels
of p120-GAP and phosphorylation of Src (Tyr416) and
of ERK (Figure 4C). While p120-GAP was not reduced,
ras activity and phospho-Src levels were significantly
l o w e ri nS u 8 6 8 6a n d8 9 8 8Tc e l l s( b o t hc e l ll i n e s
demonstrated the comparably highest Ras activity, Fig-
ure 4A) at 24 h after RNAi. Levels of phosphorylated
ERK decreased gradually, reaching the minimum at 72 h
in SDC-2 transfected Su8686 cells. These results suggest
that SDC-2 signaling merges into the K-ras/MAPK
pathway. Interestingly, no modifications of these pro-
teins were detected in T3M4 and Panc1 cancer cells
(Figure 4C and data not shown).
Discussion
Local and perineural invasion are prominent characteris-
tics of pancreatic cancer which are thought to contri-
bute to its particular aggressiveness and also to the
severe pain syndrome associated with the disease
[22,45]. A deeper understanding of the underlying mole-
cular mechanisms is strongly needed to be able to
directly target these properties. We have recently devel-
oped a novel in vitro model of perineural invasion of
pancreatic cancer cells which we used to determine a
number of genes which are deregulated when the cells
become more invasive [12]. Using this model, we found
syndecan-2 upregulation in nerve-invasive pancreatic
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Figure 4 A, ras-activity assay in pancreatic cancer cell lines Colo-357, Panc-1, T3M4, Su8686, 8988 T (all K-ras-mutated) and BxPC3
(wild-type K-ras); B, immunoprecipitation with an anti-SDC-2 antibody; lysates from BxPC3 and Su8686 cells (left panel); blotting with
an anti-p120GAP antibody (right panel); C, immunoblot following SDC-2 RNAi: p120GAP, ras-activity (ras-GTP), total and phospho-Src
(Tyr416), total and phospho-ERK; “Fold expression” has been calculated using densitometry of the immunoblots normalized to
GAPDH; D, schematic SDC2 signaling in 1, non-transformed cells (WT ras) with “normal” ras activity and in 2, (malignant) transformed
cells (ras-mutated) with ras overactivity.
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can-2 modulates invasiveness of pancreatic cancer cells
in culture and may interferes with K-ras/MAPK signaling
as one of the predominantly deregulated pathways in
PDAC. This is of particular interest since it has been
demonstrated by a number of reports that there is a link
between syndecan-2 and oncogenic ras signaling. Firstly,
in non-transformed-ras cells, the scaffolding protein
RACK1 (receptor for activated C-kinase 1) is bound as a
heterodimer to the cytoplasmic domain of SDC-2.
Furthermore, it has been demonstrated that in cells
transformed by oncogenic ras, RACK1 is no longer
bound to the SDC-2 cytoplasmatic tail, and that the
GTPase activation protein GAP (p120-GAP) that nega-
tively regulates ras activity, and normally is not translo-
cated to the plasma membrane was highly expressed and
that its localization overlapped with SDC-2. This com-
plex (SDC2/p120-GAP) can provide a docking site for
Src to prosecute tyrosine kinase activity, maintaining Src
in an active form [40]. In contrast, following oncogenic
transformation by overactivation of ras, RACK-1 is
dimerized and thus no longer bound to the SDC-2 tail.
This leads to a) a perpetuation of the K-ras signal by the
RACK1 dimer and b) to binding of p120-GAP to SDC2
and thus to the loss of the inhibitory p120-GAP signal on
K-ras-GTP [41,42]. It is important to point out that when
we silenced SDC-2 expression, p120GAP protein levels
were not altered, suggesting that p120GAP might nega-
tively regulate ras activity. These results would be in line
with recent reports and underline the importance of syn-
decan-2 signaling in K-ras overactive (transformed) cells
(Figure 4D, 1: normal ras activity; 2: ras overactivity).
Furthermore, we have silenced SDC2 in T3M4 and
Panc1 pancreatic cancer cell lines. Here, we did not find
the changes as observed in Su8686 and 8988 T cells, sug-
gesting that these effects are due to the different Kras-
status of these cells (although Panc1 and T3M4 cells also
have a high SDC-2 expression (Figure 1B), K-ras is not
constantly active). Interestingly, a recent study showed
that there are two classes of pancreatic cancer cell lines:
those which require K-ras to maintain viability (K-ras
dependent) and those which do not (independent) [4].
Our findings that silencing of SDC-2 not only reduces
Src Tyr416 phosphorylation and ras activity, but also
(downstream) ERK phosphorylation, might be interpreted
in two ways: firstly, Su8686 pancreatic cancer cells are K-
ras-independent and syndecan-2 RNAi signals to K-ras as
well as directly into the MAPK pathway or secondly,
Su8686 cells are K-ras-dependent and ablation of the
(intact) K-ras signal effects its downstream targets and
thus reduces invasiveness and migration. Our in vitro
results using pancreatic cancer cells are similar to a pre-
viously published report [20], where SDC-2 induced the
migratory activity of melanoma cells through activation
of FAK, which directly and indirectly interacts not only
with MAPK and Src signaling, but also with CDC42, Cor-
tactin and WAVE.
Furthermore, a recent study from Hrabar et al. [46]
showed comparable immunohistochemical results
regarding SDC-2 expression in pancreatic cancer. In
contrast to our results, SDC-2 expression correlated
with survival on multivariable analysis, and patients with
higher SDC-2 expression had a distinctly longer survival.
Differences in the number of patients analyzed may
explain these different results.
The exact mechanisms underlying these differences
and our functional observations will be the subject of
further analyses; however, reduction of the invasive and
migratory potential without effecting proliferation of the
cancer cells could be an appealing approach to target a
de-regulated system without inducing too much selec-
tive pressure on the cancer cells which might result in
tumor-therapy evasion.
Conclusions
In conclusion, we demonstrate that syndecan-2 is an
important mediator of pancreatic cancer cell invasive-
ness and that it cooperates with oncogenic K-ras in the
induction of a (more) malignant phenotype. The results
of this study thus lay the basis for an in-depth analysis
of the interference in de-regulated syndecan signaling in
pancreatic cancer (perineural) invasion.
Abbreviations
PDAC: Pancreatic ductal adenocarcinoma; CP: Chronic pancreatitis; NP:
Normal pancreas; PNI: Perineural invasion; SDC-2: Syndecan-2; RNAi: RNA
interference; IHC: Immunohistochemistry; IF: Immunofluorescence; WB:
Western blot; WT: Wild-type; IP: Immunoprecipitation.
Acknowledgements
We thank Alexander Herner, Felicitas Altmayer, Tanja Roßmann, Manja
Thorwirth and Monika Hane for their indispensable help and technical
support. This study was supported by a grant from the Deutsche Krebshilfe
107750 (JK).
Author details
1Department of Surgery, Technische Universität München, Munich, Germany.
2International Max Planck Research School, Martinsried-Munich, Germany.
Authors’ contributions
TDO, IA, SR and DS carried out the experiments; TDO, IA, SR, DS, ME, BK and
CWM analyzed data. TDO, CWM, IA, HF and JK drafted the manuscript. CWM,
TDO, ME, BK, HF and JK designed the study. HF, JK and CWM coordinated
the study. All authors read and approved the final draft of the manuscript.
TDO and IA contributed equally to the study.
Competing interests
The authors declare that they have no competing interests.
Received: 15 December 2010 Accepted: 3 April 2012
Published: 3 April 2012
References
1. Jemal A, et al: CA Cancer J Clin 2008, 58(2):71-96.
De Oliveira et al. Molecular Cancer 2012, 11:19
http://www.molecular-cancer.com/content/11/1/19
Page 9 of 102. Dai H, et al: Enhanced survival in perineural invasion of pancreatic
cancer: an in vitro approach. Hum Pathol 2007, 38(2):299-307.
3. Kleeff J, et al: Pancreatic cancer microenvironment. Int J Cancer 2007,
121(4):699-705.
4. Singh A, et al: A gene expression signature associated with “K-Ras
addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell
2009, 15(6):489-500.
5. Campbell PM, et al: K-Ras promotes growth transformation and invasion
of immortalized human pancreatic cells by Raf and phosphatidylinositol
3-kinase signaling. Cancer Res 2007, 67(5):2098-2106.
6. Esposito I, et al: Most pancreatic cancer resections are R1 resections. Ann
Surg Oncol 2008, 15(6):1651-1660.
7. Gotte M: Syndecans in inflammation. FASEB J 2003, 17(6):575-591.
8. Munesue S, et al: A novel function of syndecan-2, suppression of matrix
metalloproteinase-2 activation, which causes suppression of metastasis.
J Biol Chem 2007, 282(38):28164-28174.
9. Couchman JR: Syndecans: proteoglycan regulators of cell-surface
microdomains? Nat Rev Mol Cell Biol 2003, 4(12):926-937.
10. Parish CR: The role of heparan sulphate in inflammation. Nat Rev
Immunol 2006, 6(9):633-643.
11. Conejo JR, et al: Syndecan-1 expression is up-regulated in pancreatic but
not in other gastrointestinal cancers. Int J Cancer 2000, 88(1):12-20.
12. Abiatari I, et al: Consensus transcriptome signature of perineural invasion
in pancreatic carcinoma. Mol Cancer Ther 2009, 8(6):1494-1504.
13. Kaur C, et al: Expression of syndecan-2 in the amoeboid microglial cells
and its involvement in inflammation in the hypoxic developing brain.
Glia 2009, 57(3):336-349.
14. Granes F, et al: Ezrin links syndecan-2 to the cytoskeleton. J Cell Sci 2000,
113(Pt 7):1267-1276.
15. Landgraf P, et al: The survival-promoting peptide Y-P30 enhances
binding of pleiotrophin to syndecan-2 and -3 and supports its
neuritogenic activity. J Biol Chem 2008, 283(36):25036-25045.
16. Klass CM, Couchman JR, Woods A: Control of extracellular matrix
assembly by syndecan-2 proteoglycan. J Cell Sci 2000, 113(Pt 3):493-506.
17. Munesue S, et al: The role of syndecan-2 in regulation of actin-
cytoskeletal organization of Lewis lung carcinoma-derived metastatic
clones. Biochem J 2002, 363(Pt 2):201-209.
18. Park H, et al: Syndecan-2 mediates adhesion and proliferation of colon
carcinoma cells. J Biol Chem 2002, 277(33):29730-29736.
19. Kim Y, et al: Decreased syndecan-2 expression correlates with
trichostatin-A induced-morphological changes and reduced tumorigenic
activity in colon carcinoma cells. Oncogene 2003, 22(6):826-830.
20. Lee JH, et al: Syndecan-2 regulates the migratory potential of melanoma
cells. J Biol Chem 2009, 284(40):27167-27175.
21. Jiang X, et al: Pancreatic islet and stellate cells are the main sources of
endocrine gland-derived vascular endothelial growth factor/prokineticin-
1 in pancreatic cancer. Pancreatology 2009, 9(1-2):165-172.
22. Michalski CW, et al: Cannabinoids in pancreatic cancer: correlation with
survival and pain. Int J Cancer 2008, 122(4):742-750.
23. Abiatari I, et al: Moesin Dependent Cytoskeleton Remodeling Is
Associated with an Anaplastic Phenotype of Pancreatic Cancer. J Cell Mol
Med 2009, 14(5):1166-1179.
24. Michalski CW, et al: Cannabinoids reduce markers of inflammation and
fibrosis in pancreatic stellate cells. PLoS One 2008, 3(2):e1701.
25. Kayed H, et al: BGLAP is expressed in pancreatic cancer cells and
increases their growth and invasion. Mol Cancer 2007, 6:83.
26. Couchman JR, Chen L, Woods A: Syndecans and cell adhesion. Int Rev
Cytol 2001, 207:113-150.
27. Oh ES, Woods A, Couchman JR: Multimerization of the cytoplasmic
domain of syndecan-4 is required for its ability to activate protein
kinase C. J Biol Chem 1997, 272(18):11805-11811.
28. Contreras HR, et al: The expression of syndecan-1 and -2 is associated
with Gleason score and epithelial-mesenchymal transition markers, E-
cadherin and beta-catenin, in prostate cancer. Urol Oncol 2010,
28(5):534-540.
29. Orosco A, et al: Syndecan-2 affects the basal and chemotherapy-induced
apoptosis in osteosarcoma. Cancer Res 2007, 67(8):3708-3715.
30. Choi S, et al: Syndecan-2 overexpression regulates adhesion and
migration through cooperation with integrin alpha2. Biochem Biophys Res
Commun 2009, 384(2):231-235.
31. Han I, Park H, Oh ES: New insights into syndecan-2 expression and
tumourigenic activity in colon carcinoma cells. J Mol Histol 2004,
35(3):319-326.
32. Sun C, et al: Characterization of the mutations of the K-ras, p53, p16, and
SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep 2001,
8(1):89-92.
33. Tkachenko E, Rhodes JM, Simons M: Syndecans: new kids on the signaling
block. Circ Res 2005, 96(5):488-500.
34. Oh ES, Woods A, Couchman JR: Syndecan-4 proteoglycan regulates the
distribution and activity of protein kinase C. J Biol Chem 1997,
272(13):8133-8136.
35. Dews IC, Mackenzie KR: Transmembrane domains of the syndecan family
of growth factor coreceptors display a hierarchy of homotypic and
heterotypic interactions. Proc Natl Acad Sci USA 2007,
104(52):20782-20787.
36. Bhatt AS, et al: Adhesion signaling by a novel mitotic substrate of src
kinases. Oncogene 2005, 24(34):5333-5343.
37. Jones RJ, et al: Elevated c-Src is linked to altered cell-matrix adhesion
rather than proliferation in KM12C human colorectal cancer cells. Br J
Cancer 2002, 87(10):1128-1135.
38. Kinnunen T, et al: Cortactin-Src kinase signaling pathway is involved in
N-syndecandependent neurite outgrowth. J Biol Chem 1998,
273(17):10702-10708.
39. Granes F, et al: Identification of a novel Ezrin-binding site in syndecan-2
cytoplasmic domain. FEBS Lett 2003, 547(1-3):212-216.
40. Huang JW, Chen CL, Chuang NN: P120-GAP associated with syndecan-2
to function as an active switch signal for Src upon transformation with
oncogenic ras. Biochem Biophys Res Commun 2005, 329(3):855-862.
41. Huang JW, Chuang NN: Shift syndecan-2 from RACK1 to caveolin-2 upon
transformation with oncogenic ras. Biochem Biophys Res Commun 2006,
350(1):227-232.
42. Chu LY, Chen YH, Chuang NN: Dimerize RACK1 upon transformation with
oncogenic ras. Biochem Biophys Res Commun 2005, 330(2):474-482.
43. Sipos B, et al: A comprehensive characterization of pancreatic ductal
carcinoma cell lines: towards the establishment of an in vitro research
platform. Virchows Arch 2003, 442(5):444-452.
44. Kalthoff H, et al: p53 and K-RAS alterations in pancreatic epithelial cell
lesions. Oncogene 1993, 8(2):289-298.
45. Schweizerhof M, et al: Hematopoietic colony-stimulating factors mediate
tumor-nerve interactions and bone cancer pain. Nat Med 2009,
15(7):802-807.
46. Hrabar D, et al: Epithelial and stromal expression of syndecan-2 in
pancreatic carcinoma. Anticancer Res 2010, 30(7):2749-2753.
doi:10.1186/1476-4598-11-19
Cite this article as: De Oliveira et al.: Syndecan-2 promotes perineural
invasion and cooperates with K-ras to induce an invasive pancreatic
cancer cell phenotype. Molecular Cancer 2012 11:19.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
De Oliveira et al. Molecular Cancer 2012, 11:19
http://www.molecular-cancer.com/content/11/1/19
Page 10 of 10